Ipsen S.A (I7G) - Total Assets
Based on the latest financial reports, Ipsen S.A (I7G) holds total assets worth €6.83 Billion EUR as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ipsen S.A - Total Assets Trend (2013–2024)
This chart illustrates how Ipsen S.A's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ipsen S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
Ipsen S.A's total assets of €6.83 Billion consist of 31.4% current assets and 68.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.5% |
| Accounts Receivable | €697.20 Million | 10.8% |
| Inventory | €285.50 Million | 4.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.52 Billion | 39.1% |
| Goodwill | €699.50 Million | 10.9% |
Asset Composition Trend (2013–2024)
This chart illustrates how Ipsen S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ipsen S.A's current assets represent 31.4% of total assets in 2024, a decrease from 38.5% in 2013.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2024, up from 8.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 28.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 39.1% of total assets.
Ipsen S.A Competitors by Total Assets
Key competitors of Ipsen S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩642.17 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp Preferred
KO:000105
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma
KO:000220
|
Korea | ₩202.42 Billion |
|
Ildong Holdings Co Ltd
KO:000230
|
Korea | ₩813.62 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Ipsen S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.98 | 1.80 | 1.06 |
| Quick Ratio | 1.80 | 1.58 | 0.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.40 Billion | €1.06 Billion | €76.20 Million |
Ipsen S.A - Advanced Valuation Insights
This section examines the relationship between Ipsen S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.08 |
| Latest Market Cap to Assets Ratio | 2.02 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | €6.44 Billion |
| Market Capitalization | $13.04 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ipsen S.A's assets at a significant premium (2.02x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Ipsen S.A's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ipsen S.A (2013–2024)
The table below shows the annual total assets of Ipsen S.A from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €6.44 Billion | +1.84% |
| 2023-12-31 | €6.32 Billion | +12.75% |
| 2022-12-31 | €5.61 Billion | +12.01% |
| 2021-12-31 | €5.01 Billion | +15.97% |
| 2020-12-31 | €4.32 Billion | +0.24% |
| 2019-12-31 | €4.31 Billion | +27.52% |
| 2018-12-31 | €3.38 Billion | +9.94% |
| 2017-12-31 | €3.07 Billion | +26.76% |
| 2016-12-31 | €2.42 Billion | +25.05% |
| 2015-12-31 | €1.94 Billion | +13.12% |
| 2014-12-31 | €1.71 Billion | +9.46% |
| 2013-12-31 | €1.57 Billion | -- |
About Ipsen S.A
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more